ProQR Therapeutics N.V.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| PRQR | EDIT | DTIL | SCTX | PRME | KRRO | |
|---|---|---|---|---|---|---|
| Market cap | 198.98M | 417.74M | 226.84M | 317.67M | 901.44M | 244.74M |
| P/E (TTM) | — | — | 32.5 | — | — | — |
| Forward P/E | -3.0 | -3.6 | -4.4 | -4.6 | -5.6 | -3.8 |
| Price/book | 2.2 | 4.0 | 4.4 | -0.3 | 22.1 | 2.4 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −42.44% | −6.47% | +5.29% | −14.60% | +3.41% | −50.97% |
| Today | +2.92% | +4.62% | +16.50% | +3.58% | +9.23% | +4.79% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All PRQR news ›ProQR Therapeutics N.V. (PRQR) Presents at TIDES Europe 2026 - Slideshow
2026-11-04. The following slide deck was published by ProQR Therapeutics N.V. The following slide deck was published by ProQR Therapeutics N.V. in conjunction with this event.
Reviewing ProQR Therapeutics (PRQR) & The Competition
Posted by Danessa Lincoln on Oct 31st, 2026 ProQR Therapeutics (NASDAQ:PRQR – Get Free Report) is one of 844 public companies in the “Biotechnology” industry, but how does it contrast to its peers? We will compare ProQR Therapeutics to…
ProQR Therapeutics doses first participant in AX-0811 clinical trial
ProQR Therapeutics (PRQR) announced that the first participant has been dosed in the Phase 1 clinical trial of AX-0811 in healthy volunteers. ... ProQR Therapeutics doses first participant in AX-0811 clinical trial ProQR Therapeutics…
ProQR Therapeutics management to meet with Oppenheimer
Meeting to be held in Denver on October 15 and in San Francisco on October 16 hosted by Oppenheimer. Published first on TheFly – the ultimate s... ProQR Therapeutics management to meet with Oppenheimer Meeting to be held in Denver on…
ProQR Announces Appointment of Chris Hart as Chief Data and AI Officer and Thomas Wolf to join the Board of Directors as Strategic AI Advisor
LEIDEN, Netherlands & CAMBRIDGE, Mass., Sept. 23, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a clinical-stage company dedicated to changing lives through transformative RNA therapies based on its proprietary…
ProQR Therapeutics N.V. to Present Clinical and Preclinical Progress from AX-0810 and AX-0811 at Upcoming Conferences
ProQR Therapeutics N.V. announced upcoming presentations highlighting clinical and preclinical progress with AX-0810 and AX-0811 and the broader Axiomer RNA editing platform at TIDES Europe, The Liver Meeting 2026, and Nature Conferences…
ProQR Therapeutics (NASDAQ:PRQR) & Capricor Therapeutics (NASDAQ:CAPR) Head-To-Head Contrast
Posted by Mitch Edgeman on Oct 26th, 2026 ProQR Therapeutics (NASDAQ:PRQR – Get Free Report) and Capricor Therapeutics (NASDAQ:CAPR – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will…
Financial Comparison: ProQR Therapeutics (NASDAQ:PRQR) vs. Beam Therapeutics (NASDAQ:BEAM)
Posted by Danessa Lincoln on Oct 11th, 2026 ProQR Therapeutics (NASDAQ:PRQR – Get Free Report) and Beam Therapeutics (NASDAQ:BEAM – Get Free Report) are both healthcare companies, but which is the superior business? We will contrast the…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- markets.businessinsider.com4
- themarketsdaily.com3
- nasdaq.com1
- seekingalpha.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 9 articles, not a forecast.